Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.

[1]  V. Cogliano.  International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.

[2]  L. Denny,et al.  FIGO Cancer Report 2018 , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  I. Christensen,et al.  Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). , 2016, Gynecologic oncology.

[4]  M. Quinn,et al.  FIGO Cancer Report 2015 , 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  V. Turan,et al.  Should we remove the normal-looking appendix during operations for borderline mucinous ovarian neoplasms?: A retrospective study of 129 cases. , 2015, International journal of surgery.

[6]  O. Mogensen,et al.  The Value of Random Biopsies, Omentectomy, and Hysterectomy in Operations for Borderline Ovarian Tumors , 2014, International Journal of Gynecologic Cancer.

[7]  K. K. van de Vijver,et al.  Mucinous borderline tumours of the ovary and the appendix: a retrospective study and overview of the literature. , 2014, Gynecologic oncology.

[8]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[9]  N. Teng,et al.  The omentum and omentectomy in epithelial ovarian cancer: a reappraisal: part II--The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. , 2013, Gynecologic oncology.

[10]  L. Selvaggi,et al.  Borderline Epithelial Tumors of the Ovary , 2013 .

[11]  J. Berek,et al.  Cancer of the ovary, fallopian tube, and peritoneum , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[12]  E. Darai,et al.  Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. , 2012, The Lancet. Oncology.

[13]  P. Suprasert,et al.  Accuracy of Frozen-Section Diagnosis of Ovarian Mucinous Tumors , 2012, International Journal of Gynecologic Cancer.

[14]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[15]  P. Suprasert,et al.  Mucinous Tumor of Low Malignant Potential (“Borderline” or “Atypical Proliferative” Tumor) of the Ovary: A Study of 171 Cases With the Assessment of Intraepithelial Carcinoma and Microinvasion , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[16]  J. Baak,et al.  Neoplastic transformation of endocervicosis into an extraovarian mucinous cystadenocarcinoma. , 2011, Human pathology.

[17]  R. Kurman,et al.  The Fallopian Tube-Peritoneal Junction: A Potential Site of Carcinogenesis , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[18]  C. Haie-meder,et al.  Prognostic Factors of a Large Retrospective Series of Mucinous Borderline Tumors of the Ovary (Excluding Peritoneal Pseudomyxoma) , 2010, Annals of Surgical Oncology.

[19]  Kathleen R. Cho,et al.  Ovarian cancer update: lessons from morphology, molecules, and mice. , 2009, Archives of pathology & laboratory medicine.

[20]  A. Ayhan,et al.  Omentectomy for gynecologic cancer: how much sampling is adequate for microscopic examination? , 2007, Archives of pathology & laboratory medicine.

[21]  P. Neven,et al.  Management of borderline ovarian neoplasms. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Brännström,et al.  Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period , 2007, International Journal of Gynecologic Cancer.

[23]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  S. Robboy,et al.  Is Stromal Microinvasion in Primary Mucinous Ovarian Tumors With “Mucin Granuloma” True Invasion? , 2007, The American journal of surgical pathology.

[25]  N. Yaegashi,et al.  Clinical outcome and risk factors for recurrence in borderline ovarian tumours , 2006, British Journal of Cancer.

[26]  P. Morice,et al.  Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. , 2004, European journal of cancer.

[27]  E. Daraï,et al.  Restaging surgery for women with borderline ovarian tumors , 2004, Cancer.

[28]  R. Young,et al.  The Distinction Between Primary and Metastatic Mucinous Carcinomas of the Ovary: Gross and Histologic Findings in 50 Cases , 2003, The American journal of surgical pathology.

[29]  J. Nicklin,et al.  Evaluation of restaging in clinical stage 1A low malignant potential ovarian tumours , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.

[30]  C. Mangioni,et al.  Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[32]  G. Stuart,et al.  Evaluation of surgical staging in stage I low malignant potential ovarian tumors. , 1991, Gynecologic oncology.